Hiromi Kazuno

Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models

Nozomu Tanaka, Kazuki Sakamoto, Hiroyuki Okabe et al. · Oncology Reports · 2014 · 140 citations · Full text

Antitumor Activity, Medicine, Tumor Growth +14

TAS4464, A Highly Potent and Selective Inhibitor of NEDD8-Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models

Chihoko Yoshimura, Hiromi Muraoka, Hiroaki Ochiiwa et al. · Molecular Cancer Therapeutics · 2019 · 65 citations

Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2′-deoxy-5-fluorouridine into DNA

Kazuki Sakamoto, Tatsushi Yokogawa, Hiroyuki Ueno et al. · International Journal of Oncology · 2015 · 57 citations · Full text

Prior Therapies, Molecular Biology, Crucial Roles +19

Sensitivity of Human Cancer Cells to the New Anticancer <i>Ribo</i>‐nucleoside TAS–106 Is Correlated with Expression of Uridine‐cytidine Kinase 2

Yuji Shimamoto, Katsuhisa Koizumi, Hiroyuki Okabe et al. · Japanese Journal of Cancer Research · 2002 · 54 citations · Full text

Uridine‐cytidine Kinase 2, Cancer Biology, Tumor Biology +20

Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use

Satoru Ito, Sachie Otsuki, Hirokazu Ohsawa et al. · ACS Medicinal Chemistry Letters · 2023 · 31 citations · Full text